Phase II study of cetuximab [Erbitux] for the refractory or relapsed multiple myeloma EMMA-1 (Erbitux for Multiple Myeloma).
Phase of Trial: Phase II
Latest Information Update: 29 Apr 2015
At a glance
- Drugs Cetuximab; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms EMMA-1
- 12 Jul 2012 Actual end date changed from 30 Nov 2009 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 30 Nov 2009 Actual end date (30 Nov 2009) added as reported by ISRCTN: Current Controlled Trials.